1. Home
  2. LMAT vs NVCR Comparison

LMAT vs NVCR Comparison

Compare LMAT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$97.78

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$17.90

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
NVCR
Founded
1983
2000
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
1.2B
IPO Year
2006
2015

Fundamental Metrics

Financial Performance
Metric
LMAT
NVCR
Price
$97.78
$17.90
Analyst Decision
Buy
Buy
Analyst Count
5
6
Target Price
$105.80
$28.08
AVG Volume (30 Days)
223.4K
1.8M
Earning Date
05-05-2026
04-30-2026
Dividend Yield
0.93%
N/A
EPS Growth
30.57
21.79
EPS
0.68
N/A
Revenue
$249,602,000.00
$655,353,000.00
Revenue This Year
$14.21
$7.72
Revenue Next Year
$8.88
$6.74
P/E Ratio
$146.62
N/A
Revenue Growth
13.53
8.28
52 Week Low
$79.01
$9.82
52 Week High
$118.01
$20.05

Technical Indicators

Market Signals
Indicator
LMAT
NVCR
Relative Strength Index (RSI) 35.56 66.10
Support Level $82.65 $12.48
Resistance Level $99.95 $18.92
Average True Range (ATR) 4.66 0.90
MACD -0.63 -0.08
Stochastic Oscillator 11.95 70.74

Price Performance

Historical Comparison
LMAT
NVCR

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: